We are live on
!
Find out more
SAM
Senzar Asset Management Portfolio holdings
AUM
$34.7M
1-Year Est. Return
0.56%
This Fund
S&P 500
This Quarter
Est. Return
+1.2%
1 Year Est. Return
+0.56%
3 Year Est. Return
-0.75%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$392M
AUM Growth
-$18M
(-4.4%)
Cap. Flow
-$36.6M
Cap. Flow
% of AUM
-9.34%
Top 10 Holdings %
Top 10 Hldgs %
63.12%
Holding
39
New
11
Increased
9
Reduced
9
Closed
10
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AET
Aetna Inc
AET
|
+$24.1M |
| 2 |
Viatris
VTRS
|
+$23.2M |
| 3 |
CVS Health
CVS
|
+$22.9M |
| 4 |
Novartis
NVS
|
+$17.3M |
| 5 |
Abbott
ABT
|
+$17M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Halozyme
HALO
|
+$60.5M |
| 2 |
TSRO
TESARO, Inc.
TSRO
|
+$28.3M |
| 3 |
AGN.PRA
Allergan plc
AGN.PRA
|
+$28.1M |
| 4 |
Elevance Health
ELV
|
+$24.1M |
| 5 |
Encompass Health
EHC
|
+$16.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 77.53% |
| 2 | Financials | 6.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
Sanofi
SNY
$105B
| $43M | 10.98% |
999,786
+202,300
| +25% | +$9.33M |
|
2
Regeneron Pharmaceuticals
REGN
$68.3B
| $42.7M | 10.89% |
113,500
+36,200
| +47% | +$14.7M |
|
|
3
Viatris
VTRS
$19.8B
| $25.7M | 6.55% |
+606,500
| New | +$23.2M |
|
|
AET
4
DELISTED
Aetna Inc
AET
| $25.3M | 6.46% |
+140,200
| New | +$24.1M |
|
|
5
CVS Health
CVS
$138B
| $22.9M | 5.84% |
+315,500
| New | +$22.9M |
|
6
Ironwood Pharmaceuticals
IRWD
$639M
| $21.7M | 5.54% |
1,729,867
+1,124,509
| +186% | +$14.7M |
|
|
7
Abbott
ABT
$175B
| $17.5M | 4.48% |
+307,400
| New | +$17M |
|
|
8
Novartis
NVS
$292B
| $17.2M | 4.39% |
+228,668
| New | +$17.3M |
|
|
AERI
9
DELISTED
Aerie Pharmaceuticals
AERI
| $16.6M | 4.25% |
278,400
+47,200
| +20% | +$2.86M |
|
|
AGN.PRA
10
DELISTED
Allergan plc
AGN.PRA
| – | – |
-43,600
| Closed | -$28.1M |
|
|
ELGX
11
DELISTED
Endologix Inc
ELGX
| $11.8M | 3% |
219,623
+129,469
| +144% | +$6.84M |
|
|
CERN
12
DELISTED
Cerner Corp
CERN
| $11.4M | 2.91% |
+169,000
| New | +$11.7M |
|
13
TG Therapeutics
TGTX
$8.06B
| $11.1M | 2.84% |
1,355,178
+491,678
| +57% | +$4.3M |
|
14
Medtronic
MDT
$105B
| $11.1M | 2.84% |
137,600
+14,400
| +12% | +$1.15M |
|
|
15
Halozyme
HALO
$9.23B
| $10.9M | 2.78% |
537,500
-3,292,690
| -86% | -$60.5M |
|
16
MiMedx Group
MDXG
$621M
| $9.16M | 2.34% |
+726,300
| New | +$8.86M |
|
|
ALDR
17
DELISTED
Alder Biopharmaceuticals
ALDR
| $9.01M | 2.3% |
786,870
+145,700
| +23% | +$1.63M |
|
|
SEM
18
DELISTED
Select Medical
SEM
| $8.66M | 2.21% |
+910,368
| New | +$8.7M |
|
|
RVNC
19
DELISTED
Revance Therapeutics, Inc.
RVNC
| $8.45M | 2.16% |
+236,355
| New | +$6.79M |
|
|
AGN
20
DELISTED
Allergan plc
AGN
| $8M | 2.04% |
48,900
-11,200
| -19% | -$2.01M |
|
|
CNCE
21
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $7.15M | 1.83% |
276,345
-59,100
| -18% | -$1.19M |
|
|
SIEN
22
DELISTED
Sientra, Inc.
SIEN
| $6.81M | 1.74% |
48,461
+35,420
| +272% | +$5.15M |
|
|
AVXS
23
DELISTED
AveXis, Inc. Common Stock
AVXS
| $6.43M | 1.64% |
+58,100
| New | +$5.83M |
|
|
24
Encompass Health
EHC
$11B
| $5.75M | 1.47% |
146,189
-431,528
| -75% | -$16.4M |
|
|
NXTM
25
DELISTED
NxStage Medical Inc.
NXTM
| $5.17M | 1.32% |
+213,200
| New | +$5.62M |
|
Similar funds
BCP
PRHC
NAM
GG
SM
BC
SCPM
FAM
Senzar Asset Management's Q4 2017 Portfolio in Review
As of Q4 2017, Senzar Asset Management held 39 positions worth $392M, down 4.4% from $410M the previous quarter. Its ten largest holdings account for 63% of the portfolio.
Senzar Asset Management withdrew a net $36.6M in Q4 2017, closing 10 positions and reducing 9 holdings. Its most notable exit was TESARO, Inc., an estimated $28.3M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 78% of assets, down from 81% a quarter earlier, followed by Financials.
Against the trend, Senzar Asset Management opened a new position in Aetna Inc worth $25.3M.
- Senzar Asset Management's largest Q4 2017 buy was Aetna Inc: 140,200 shares worth $25.3M.
- Senzar Asset Management added most to Ironwood Pharmaceuticals in Q4 2017, an estimated $14.7M increase.
- Senzar Asset Management's biggest Q4 2017 reduction was Halozyme, cutting an estimated $60.5M.
- Senzar Asset Management fully exited TESARO, Inc. in Q4 2017, selling an estimated $28.3M.
- Senzar Asset Management's ten largest holdings make up 63% of its $392M portfolio in Q4 2017.
- Senzar Asset Management opened 11 new positions and closed 10 in Q4 2017.
- Senzar Asset Management's portfolio value fell 4.4% quarter-over-quarter to $392M.
Based on Senzar Asset Management's 13F filing for Q4 2017, filed 13 Feb 2018.